{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:30:57Z","timestamp":1774438257663,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cpcardiol.2020.100765","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T17:24:47Z","timestamp":1607707487000},"page":"100765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Myopathy Associated With Statins and SGLT2 \u2013 A Review of Literature"],"prefix":"10.1016","volume":"46","author":[{"given":"Rahul","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Alcantara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Popli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sugandhi","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umair","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raman S.","family":"Dusaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaqib H.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2020.100765_bib0001","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/pgmj.69.811.333","article-title":"Drug-induced rhabdomyolysis\u2013mechanisms and management","volume":"69","author":"Prendergast","year":"1993","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0002","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0889-857X(21)00078-8","article-title":"Drug-related myopathies","volume":"20","author":"Zuckner","year":"1994","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0003","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mus.10244","article-title":"Iatrogenic and toxic myopathies","volume":"27","author":"Sieb","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0004","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0140-6736(78)92894-5","article-title":"Drug-induced myopathies in man","volume":"2","author":"Lane","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0005","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/cvr\/cvy119","article-title":"Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence","volume":"114","author":"Brunham","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0006","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0007","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-Associated Autoimmune Myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","article-title":"Statin therapy and plasma coenzyme Q10 concentrations\u2013A systematic review and meta-analysis of placebo-controlled trials","volume":"99","author":"Banach","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0009","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archneur.61.6.889","article-title":"Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke","volume":"61","author":"Rundek","year":"2004","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0010","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study","volume":"33","author":"Ghirlanda","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0011","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.1067\/mhj.2001.116762","article-title":"The effect of pravastatin and atorvastatin on coenzyme Q10","volume":"142","author":"Bleske","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0012","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0002-9149(97)89180-1","article-title":"The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle","volume":"77","author":"Laaksonen","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0013","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","article-title":"Muscle coenzyme Q10 level in statin-related myopathy","volume":"62","author":"Lamperti","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12020-008-9126-2","article-title":"Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids","volume":"35","author":"Phillips","year":"2009","journal-title":"Endocrine"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbrc.2009.08.008","article-title":"Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression","volume":"388","author":"Iacobazzi","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0016","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0018","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0019","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0020","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0021","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s13300-020-00789-y","article-title":"Basic and clinical pharmaco-therapeutics of SGLT2 inhibitors: a contemporary update","volume":"11","author":"Kalra","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0022","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0024","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"Mcmurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0025","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0026","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.cpcardiol.2020.100765_bib0027","first-page":"S4","article-title":"Summary of Revisions: Standards of Medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0028","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0029","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0030","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0031","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep4.1019","article-title":"Effects of a sodium-glucose co-transporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies","volume":"1","author":"Akuta","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0032","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.2337\/dci18-0041","article-title":"SGLT inhibitors for type 1 diabetes: an obvious choice or too good to be true?","volume":"41","author":"Riddle","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0033","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","article-title":"SGLT inhibitor adjunct therapy in type 1 diabetes","volume":"61","author":"Mccrimmon","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0034","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7815690","article-title":"Empagliflozin increases short-term urinary volume output in artificially induced syndrome of inappropriate antidiuresis","volume":"2017","author":"Refardt","year":"2017","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0036","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/cen.13968","article-title":"Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study","volume":"90","author":"Javed","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0037","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41387-019-0098-5","article-title":"Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study","volume":"9","author":"Tang","year":"2019","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0038","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3389\/fphar.2019.01066","article-title":"Appraisal of non-cardiovascular safety for sodium-glucose co-transporter 2 inhibitors: a systematic review and meta-analysis of placebo-controlled randomized clinical trials","volume":"10","author":"Shi","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0039","doi-asserted-by":"crossref","first-page":"937","DOI":"10.7150\/ijms.22224","article-title":"Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors","volume":"15","author":"Sakaeda","year":"2018","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.metabol.2019.04.008","article-title":"Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence","volume":"96","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0041","doi-asserted-by":"crossref","first-page":"e2903","DOI":"10.1002\/dmrr.2903","article-title":"Sodium-glucose co-transporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis","volume":"33","author":"Ruanpeng","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0042","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9368583","article-title":"The impact of antidiabetic agents on sarcopenia in type 2 diabetes: a literature review","volume":"2020","author":"Wu","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000448247","article-title":"Oral drugs related with muscle wasting and sarcopenia. A review","volume":"99","author":"Campins","year":"2017","journal-title":"Pharmacology"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0044","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bone.2017.09.008","article-title":"A review of sarcopenia: enhancing awareness of an increasingly prevalent disease","volume":"105","author":"Marty","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0045","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2337\/dc09-2310","article-title":"Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS)","volume":"33","author":"Kim","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0046","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s13340-017-0339-6","article-title":"Sarcopenia in elderly patients with type 2 diabetes mellitus: prevalence and related clinical factors","volume":"9","author":"Murata","year":"2018","journal-title":"Diabetol Int"},{"issue":"3","key":"10.1016\/j.cpcardiol.2020.100765_bib0047","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/jcm8030319","article-title":"Association of glucose fluctuations with sarcopenia in older adults with type 2 diabetes mellitus","volume":"8","author":"Ogama","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0048","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/gerona\/60.10.1278","article-title":"Insulin resistance and muscle strength in older persons","volume":"60","author":"Abbatecola","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0049","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2174\/138161208783497750","article-title":"Is there a relationship between insulin resistance and frailty syndrome?","volume":"14","author":"Abbatecola","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0050","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/jdi.13014","article-title":"Association of accumulated advanced glycation end-products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes","volume":"10","author":"Mori","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0051","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/14740338.2015.1034105","article-title":"Short-term impacts of sodium\/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events","volume":"14","author":"Yabe","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0052","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jdi.13137","article-title":"Sodium-glucose co-transporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: a case report","volume":"11","author":"Yasuda","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0053","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/jdi.12705","article-title":"Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: a subgroup analysis based on patient characteristics","volume":"9","author":"Osonoi","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0054","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/dom.13421","article-title":"Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: a multicentre, randomized, prospective, open-label, active-controlled study","volume":"20","author":"Tsurutani","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0055","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41514-017-0012-0","article-title":"treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality","volume":"3","author":"Sugizaki","year":"2017","journal-title":"NPJ Aging Mech Dis"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0056","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/1753-0407.12402","article-title":"Increased grip strength with sodium-glucose co-transporter 2","volume":"8","author":"Sano","year":"2016","journal-title":"J Diabetes"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0057","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0058","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0059","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/jdi.12980","article-title":"Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"10","author":"Inoue","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0060","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1136\/jnnp.2008.168294","article-title":"Toxic and drug-induced myopathies","volume":"80","author":"Dalakas","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0061","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s11926-010-0104-3","article-title":"Drug-related myopathies of which the clinician should be aware","volume":"12","author":"Valiyil","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0062","article-title":"Myopathy secondary to empagliflozin therapy in type 2 diabetes","volume":"2020","author":"Gao","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/BJMMR\/2017\/33253","article-title":"Marked weight loss, muscle wasting and fatigue on administration of empagliflozin in a subject withtype 2 diabetes","volume":"21","author":"Kabadi","year":"2017","journal-title":"Br J Med Med Rese"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0064","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"Degorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0065","doi-asserted-by":"crossref","DOI":"10.7326\/L20-0549","article-title":"Rosuvastatin myotoxicity after starting canagliflozin treatment: a case report","author":"Brailovski","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0066","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/bcp.13186","article-title":"In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin","volume":"83","author":"Mamidi","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2020.100765_bib0067","doi-asserted-by":"crossref","first-page":"64","DOI":"10.18773\/austprescr.2015.024","article-title":"Empagliflozin","volume":"38","year":"2015","journal-title":"Aust Prescr"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280620302413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280620302413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:56:46Z","timestamp":1758938206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280620302413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0146280620302413"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2020.100765","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myopathy Associated With Statins and SGLT2 \u2013 A Review of Literature","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2020.100765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"100765"}}